I-Mab Gets Boost from Latest Industry Signals on New Cancer Treatment

Company’s shares surged as much as 15% after AstraZeneca unveiled upbeat results for a new class of cancer drugs known as CD73 antibodies Key Takeaways: I-Mab’s shares surged up to 15% on positive results from a peer developing a similar new type of cancer treatment, though they later gave back most of those gains Company has plenty of cash on hand, and could soon get more as it seeks a deal to commercialize the drug, uliledlimab, with a U.S. or European partner By Doug Young It may still be at…

Read MORE »

Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale

The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited Key takeaways: •      Less than two weeks after JW Therapeutics received regulatory approval to commercialize its core product in China, key early investor Temasek sold all of its stake •      JW Therapeutics’ stock now trades nearly 30% below its IPO price, as numerous obstacles remain in the march to commercialize its cutting-edge cancer treatment By Warren Yang It seems a major breakthrough for JW (Cayman)…

Read MORE »

New Horizon’s Sales Surge as China Promotes Early Cancer Detection

Company’s first-mover advantage in at-home colorectal screening and China’s focus on early detection have turbocharged sales, though valuation remains frothy Key takeaways: New Horizon’s first-half revenues jumped more than fourfold, assisted by government early cancer testing drive Stock volatility could owe to frothy valuation, as well as unclear timeline for profitability By Richard Barbaroza New Horizon Health Ltd. (6606.HK), a Chinese maker of self-administered tests for colorectal cancer, has reported a more than fourfold increase in revenue in the first half of 2021, buoyed by the government’s recent campaign for…

Read MORE »

Everest Medicines Ties With Tencent to Scale Last Mile to Patient Care

Back-to-back deals with Tencent and Medbanks Health seek to build new distributing partnerships ahead of expected first drug approvals Key points: Everest Medicines could gain valuable distribution channels through its new partnerships with Tencent and Medbanks Both new partners have users bases on ‘closed-loop’ healthcare platforms providing everything from checkups to drug sales By Richard Barbarossa What do cutting-edge cancer drugs and social media have in common? Not much, really. But that unlikely pairing is bringing together cancer and autoimmune disorder drug startup Everest Medicines Ltd. (1952.HK) and leading social…

Read MORE »

Biotech Aspirant Hutchmed Sails Full Steam Toward Hong Kong Homecoming IPO

Company backed by billionaire Li Ka-shing secures cornerstone investors for more than half of its $600 million secondary listing in its home market Key points:  •      Hutchmed announces new approvals in China for two of its self-developed drugs in run-up to new $600 million listing in its home market •      All seven analysts polled by Bloomberg recommend ‘buy’ for the stock, as company tries to transforms from seller of third-party drugs to developer of its own products   By Alice Leung Hong Kong Billionaire Li Ka-shing usually gets what he wants…

Read MORE »

Burning Rock Builds Up Hospital Partner Pipeline as Losses Mount

Precision cancer diagnostics developer’s fourth-quarter revenue grew 50%, as two more of its key products moved closer to commercialization Key takeaways 1)  Burning Rock’s in-hospital business could post healthy growth in 2021 due to a strong pipeline of new partner hospitals for its cancer test kits. 2)  The company has engaged in preliminary discussions with China’s regulator for approval of its new test kits for six types of cancer, which could go on sale as soon as 2022. By Richard Barbarossa Burning Rock Biotech Ltd. (NASDAQ: BNR) posted a widening…

Read MORE »